# Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

> **NCT07444606** · PHASE1 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** DNX-2401

## Key facts

- **NCT ID:** NCT07444606
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2027-01-30
- **Final completion:** 2029-01-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07444606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07444606, "Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07444606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*